8 results · 20ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

Tissue Approximation System (TAS)

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

PIC30

FDA Adverse Event
Malfunction ·WELCH ALLYN PROTOCOL, INC.·Product code MKJ·July 11, 2012

1.9F X 20CM VASCU-PICC 1.9F X 50CM VASCU-PICC

FDA 510(k)
FDA Class 2 ·General Hospital

DIMENSION TPSA CALIBRATOR, MODEL #RC459

FDA 510(k)
FDA Class 2 ·Clinical Chemistry

PROMOTE PLUS CRT-D

FDA Adverse Event
Malfunction ·ST. JUDE MEDICAL, INC., CRMD·Product code NIK·November 3, 2014

IVT DISPOSABLE

FDA Adverse Event
Malfunction ·BAXTER HEALTHCARE - MALTA·Product code KPE·August 23, 2011

UNKNOWN

FDA Adverse Event
Injury ·ETHICON INC.·Product code OTN·July 11, 2013

Brand Name: SenTiva" Product Name: VNS Therapy" SenTiva", Model 1000 Model/Catalog Number: 1000 Software Version: NA Product Description: The LivaNova VNS Therapy" System, used for Vagus Nerve Stimulation (VNS), consists of an implantable VNS Therapy generator, lead, and external programming system used to change stimulation settings. The generator is an implantable, multi-programmable pulse generator that delivers electrical signals to the vagus nerve through the lead. The generator is housed in a hermetically sealed titanium case and is powered by a single battery. Electrical signals are transmitted from the generator to the vagus nerve by the lead. The lead and the generator make up the implantable portion of the VNS Therapy System. The VNS Therapy Programming System includes a computer pre-installed with VNS Therapy programming software and a programming wand. The physician uses the programming system to read and change generator settings. The Model 1000 Generator was commercially approved for distribution in the U.S. on October 3, 2017 via PMA P970003/S210. Component: The LivaNova VNS Therapy" System, used for Vagus Nerve Stimulation (VNS).

FDA Enforcement
Class II ·Ongoing·LivaNova USA, Inc.·February 5, 2025